



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

01 January 2023
EMA/866352/2022
EMA/H/C/004961

Public statement

Trogarzo (ibalizumab)

Withdrawal of the marketing authorisation in the European Union

On 1 January 2023, the European Commission withdrew the marketing authorisation for Trogarzo (ibalizumab) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Theratechnologies Europe Limited, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Trogarzo was granted marketing authorisation in the EU on 26 September 2019 for the treatment of adults infected with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive antiviral regimen.

The marketing authorisation was initially valid for a 5-year period.

The European Public Assessment Report (EPAR) for Trogarzo will be updated to indicate that the marketing authorisation is no longer valid.

